Key Antibodies For Gall Bladder & Pancreatic

Pancreatic cancer is the 11th most common cancer in the UK; each year approximately 8500 people are diagnosed. It also the cancer with the lowest survival rate in England with 7800 deaths per year1, yet 31% of cases are said to be preventable. On the other hand, cancer accounts for less than 1% of UK cancer deaths. For those diagnosed – 3 in 20 will survive for more than ten years after diagnosis according to data from 2009-20132. Here at Menarini Diagnostics we are proud to offer a range of Biocare antibodies which may aid the identification of their respective proteins by IHC in FFPE tissues. 1Pancreatic Cancer UK, https://www.pancreaticcancer.org.uk/statistics/ Accessed [February] 2020 2Cancer Research UK, https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ Accessed [February] 2020

Key Antibodies for Gall Bladder &

Product Name Source Clone Catalog Number

β-Catenin 14 CM406 CD10 56C6 CM129 Chromogranin A LK2H10 + PHE5 CM010 Cytokeratin 7 (CK7) OV-TL 12/30 CM061 Cytokeratin 19 (CK19) Ks19.1 CM242 E-cadherin (RM) EP6 ACI3012 Glypican-3 1G12 CM396 Mucin 5AC (Gastric Mucin) 45M1 CM231 S100P Polyclonal ACI3010 Key Antibodies for Gall Bladder & Pancreatic Cancer

β-Catenin CD10 Chromogranin A β-Catenin stains the nucleus of more than CD10 is positive in pancreatic neuroendocrine Chromogranin A is present in neuroendocrine 90% of solid pseudopapillary tumors and a tumours and almost all solid pseudopapillary cells throughout the body. Almost 100% large percentage of acinar cell carcinomas tumours. Negativity is seen in pancreatic of pancreatic neuroendocrine tumours are and pancreatoblastomas. Use with CD10, E- ductal . Clear cell renal cell positive for Chromogranin. It is negative cadherin, and Chromogranin A for confirming a carcinoma metastasised to the is in pancreatic ductal adenocarcinomas, diagnosis of solid pseudopapillary tumours. often positive for CD10. solid pseudopapillary tumours and serous cystadenoma.

Cytokeratin 7 (CK7) Cytokeratin 19 (CK19) E-cadherin In acinar cell carcinoma of the pancreas, Cytokeratin 19 (CK19) is expressed in a E-cadherin expression is seen in Cytokeratin 7 (CK7) is frequently negative high percentage of pancreatic ductal pancreatic ductal adenocarcinomas, or only focally positive. In pancreatic ductal adenocarcinomas. Positivity in pancreatic acinar cell carcinomas and pancreatic carcinomas, CK7 is typically diffusely neuroendocrine tumours may be associated neuroendocrine tumours but is negative in positive, providing an aid in differentiating with a more aggressive tumour type. CK19 is solid pseudopapillary tumours. Use with these . Pancreatic neuroendocrine also often expressed in the squamous Chromogranin A, CD10 and β-catenin as a tumours are frequently negative. component of pancreatoblastomas. confirmatory diagnosis.

Glypican-3 Mucin 5AC S100P Glypican-3 is an established marker for Mucin 5AC (MUC5AC) has an important role in Expression of S100P has been reported and yolk sac tumour. pancreatic tumourigenesis. Overexpression in more than 90% of pancreatic ductal It also shows positivity in a majority of acinar has been reported in 60% to 100% of adenocarcinomas, and in gallbladder and cell carcinoma of the pancreas but negative pancreatic ductal adenocarcinomas. extrahepatic adenocarcinomas. S100P in pancreatic ductal adenocarcinomas, MUC5AC high expression has also been seen in expression is typically present in all types of pancreatic neuroendocrine tumours and solid and in gallbladder intraductal papillary mucinous . It is pseudopapillary tumours. adenocarcinomas. usually negative in acinar cell carcinomas.

KEYGALL103